NIPPON SHOKUBAI CO., LTD. has announced to acquire all shares of Lilac pharma Inc. to make Lilac pharma a 100% subsidiary on December 9, 2024.In cosmetics and pharmaceuticals, lipid nanoparticles like liposomes※1 have been drawing increasing attention as an innovative material from the point of contributing to the stability and permeability of the contained active ingredients.Lilac pharma which is a Hokkaido University-initiated startup, is developing its business based on lipid nanoparticle manufacturing technology focusing on the size of lipid nanoparticles.

日本SHOKUBAI株式会社于2024年12月9日宣布收购Lilac pharma Inc.的所有股份，使Lilac pharma成为其全资子公司。在化妆品和制药领域，脂质体※1等脂质纳米粒子作为一种创新材料，从有助于所含活性成分的稳定性和渗透性的角度来看，越来越受到人们的关注。Lilac pharma是北海道大学发起的一家初创公司，正在开发基于脂质纳米粒子制造技术的业务，重点关注脂质纳米粒子的大小。

Their own    “iLiNP®️ Microfluidic Device”2 is different from conventional method, can continuously produce high-quality lipid nanoparticles of uniformsize easily. Furthermore, since the size can be controlled widely, iLiNP®️※2 is expected to be a technology for manufacturing highly functional lipid nanoparticles and is being provided for cosmetics and pharmaceuticals.In 2017, Nippon Shokubai established the Cosmetics Business Division (at that time, the Cosmetics Business Planning Office) to promote the development of cosmetic ingredients utilizing its products and technologies, and to acquire ingredients and formulation technologies through business collaboration.

Their own    “iLiNP®️ 微流控装置“2不同于常规方法，可以连续容易地生产出均匀尺寸的高质量脂质纳米颗粒。Furthermore, since the size can be controlled widely, iLiNP®️※2 有望成为制造高功能脂质纳米颗粒的技术，并被用于化妆品和药品。2017年，日本Shokubai成立了化妆品事业部（当时是化妆品商业计划办公室），以利用其产品和技术促进化妆品成分的开发，并通过商业合作获得成分和配方技术。

Currently, Nippon Shokubai has a lineup of more than 15 cosmetic ingredients.Also the Health & Medical business Division has established synthesis and analysis technologies for middle- molecular APIs, and is developing CDMO business for oligonucleotides and peptides.Nippon Shokubai and Lilac pharma have successfully developed liposomes※1 for cosmetics with characteristics such as extremely high stability through joint research since 2019.By making Lilac pharma a 100% subsidiary, Nippon Shokubai will accelerate the development efficiency of liposomes※1 .

目前，日本Shokubai拥有超过15种化妆品成分。此外，健康与医疗事业部已经建立了中分子原料药的合成和分析技术，并正在开发寡核苷酸和肽的CDMO业务。自2019年以来，日本Shokubai和Lilac pharma通过联合研究成功开发了脂质体※1，用于化妆品，具有极高的稳定性。通过使Lilac pharma成为100%的子公司，日本Shokubai将加速脂质体※1的开发效率。